Cargando…
A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients.
Preliminary data would suggest that the pineal hormone, melatonin (MLT), may enhance tamoxifen (TMX) anti-tumour efficacy. Both MLT and TMX have been used as single agents in the palliative treatment of metastatic neoplasms, other than the classical hormone-dependent tumours, without, however, any c...
Autores principales: | Lissoni, P., Paolorossi, F., Tancini, G., Ardizzoia, A., Barni, S., Brivio, F., Maestroni, G. J., Chilelli, M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074765/ https://www.ncbi.nlm.nih.gov/pubmed/8912546 |
Ejemplares similares
-
Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone.
por: Lissoni, P., et al.
Publicado: (1995) -
A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
por: Lissoni, P., et al.
Publicado: (1994) -
Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumours.
por: Lissoni, P., et al.
Publicado: (1989) -
Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract.
por: Lissoni, P., et al.
Publicado: (1993) -
Decrease in cholesterol levels during the immunotherapy of cancer with interleukin-2.
por: Lissoni, P., et al.
Publicado: (1991)